Dr. David Hough
Dr. David Hough
Chief Medical Officer
David Hough, MD is the Chief Medical Officer at Freedom Biosciences. Prior to joining Freedom, Dr. Hough spent 17 years in various leadership roles at Janssen Research and Development, LLC (a Johnson & Johnson company). Most recently, he was the leader of the compound development team working on Spravato (esketamine). In this role, Dr. Hough oversaw the program through the development of novel indications for two severe mood disorders, and was responsible for all the medical, scientific, manufacturing, quality, preclinical, and commercial aspects of the program.
He also worked as the schizophrenia disease area leader, and led the development team for Paliperidone, a leading drug used to treat schizophrenia and schizoaffective disorder. He played a pivotal role in the development programs for oral INVEGA (paliperidone), INVEGA SUSTENNA/XEPLION (paliperidone palmitate) 1-month and 3-month formulations.
Dr. Hough is a graduate of West Point and served for several years as a regular Army officer, before earning his MD at the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland, where he later held an Adjunct Assistant Professor of Psychiatry position. After completing residency training in Psychiatry at Walter Reed Medical Center in Washington, D.C., he completed a two-year research fellowship in Clinical Pharmacology jointly sponsored by USUHS and Walter Reed Army Institute of Research. Dr. Hough served for 10 years as an Army psychiatrist at two community hospitals and on faculty at a psychiatry residency program in Honolulu, Hawaii, and is board-certified in both Adult and Geriatric Psychiatry.
He has authored numerous publications in peer-reviewed journals, is a reviewer for several journals, and served as an examiner for the American Board of Psychiatry and Neurology.
